NCT02477865 - Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients | Biotech Hunter

Enrollment

406

Participants

Timeline

Start Date

March 23, 2014

Primary Completion Date

May 15, 2016

Study Completion Date

February 28, 2017

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

PEX168(100µg)

100µg,Subcutaneous injection,once a week. continued for 52 weeks

DRUG

PEX168(200µg)

200µg,Subcutaneous injection,once a week. continued for 52 weeks

DRUG

Placebo

0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.